肿瘤学市场规模、份额、增长分析、按癌症诊断/治疗、按癌症类型、按最终用途、按地区 - 行业预测，2024-2031 年

2022年全球肿瘤市场规模约2018亿美元，高于2023年的2,244亿美元，预测期内（2024-2031年）复合年增长率为11.2%，到2031年将达到4718亿美元。 。

癌症是世界上第三大致命疾病，仅次于心血管疾病、寄生虫疾病和感染疾病。因此，由于迫切需要有效的治疗解决方案，肿瘤市场正在经历显着成长。化学预防，即使用合成或天然存在的化学物质来抑制癌变，正变得越来越重要。目前的癌症治疗方法包括手术、放射线治疗和药物介入。手术仍然是早期癌症的主要治疗方法，对于局部肿瘤，放射线治疗通常与手术一起进行。此外，药物治疗，特别是使用各种细胞毒药物的化疗，在治疗策略中扮演重要角色。针对促进癌细胞增殖和转移的特定基因变化的标靶治疗正在成为有前途的治疗方法。由于酒精和烟草消费量的增加，癌症盛行率不断上升，凸显了创新解决方案的紧迫性。因此，产业公司正在大力投资开发旨在解决多种恶性的新型治疗候选药物。随着相关人员继续寻求治疗方法的进步，这种对研究和开发的关注预计将在预测期内改善治疗结果并推动市场成长。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 监管分析
• 案例研究分析
• 技术分析
• 价格分析
• 临床试验

肿瘤市场：按癌症诊断和治疗分类

• 市场概况
• 癌症诊断
  • 切片检查
  • 影像
  • 免疫组织化学
  • 肿瘤生物标记检测
  • 原位杂交
  • 液态生物检体
• 癌症治疗
  • 标靶治疗
  • 化疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 其他的

肿瘤市场：市场：依适应症分类

• 市场概况
• 肺癌
• 大肠直肠癌
• 乳癌
• 肝癌
• 膀胱癌
• 头颈癌
• 摄护腺癌
• 其他的

肿瘤学市场：依最终用途分类

• 市场概况
• 医院
• 诊断实验室
• 影像诊断中心
• 学术界
• 专科诊所
• 其他的

肿瘤学市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Roche Holding AG
• Novartis International AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca plc
• Johnson & Johnson（Janssen Pharmaceuticals）
• Eli Lilly and Company
• Amgen Inc.
• Sanofi SA
• Bayer AG
• Takeda Pharmaceutical Company
• AbbVie Inc.
• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Celgene Corporation（acquired by Bristol-Myers Squibb）
• Regeneron Pharmaceuticals, Inc.
• GlaxoSmithKline plc（GSK）
• Daiichi Sankyo Company, Limited
• Seagen Inc.

Global Oncology Market size was valued at around USD 201.8 billion in 2022 and is expected to rise from USD 224.4 billion in 2023 to reach a value of USD 471.8 billion by 2031, at a CAGR of 11.2% over the forecast period (2024-2031).

Cancer ranks as the third most lethal disease globally, trailing only behind cardiovascular, parasitic, and infectious diseases. As a result, the market for oncology is experiencing significant growth driven by the urgent need for effective treatment solutions. Chemoprevention, which involves using synthetic or naturally occurring chemicals to inhibit carcinogenesis, is becoming increasingly relevant. Current cancer treatment methodologies encompass surgery, radiation therapy, and pharmacological interventions. Surgery remains the primary treatment choice for early-stage cancer, while radiotherapy is often employed alongside surgical procedures for localized tumors. Additionally, pharmacotherapy, particularly chemotherapy that utilizes a variety of cytotoxic agents, plays a crucial role in management strategies. Targeted therapy, which addresses specific genetic alterations in cancer cells that promote their growth and metastasis, is gaining traction as a promising treatment avenue. The escalating prevalence of cancer due to rising alcohol and tobacco consumption underscores the urgency for innovative solutions. Consequently, industry players are heavily investing in the development of novel therapeutic candidates aimed at addressing the diverse spectrum of malignancies. This focus on research and development is poised to enhance treatment outcomes and propel market growth throughout the forecast period, as stakeholders continue to seek advancements in oncology therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Market Segmental Analysis

Global Oncology Market is segmented by Cancer Diagnostics & Treatment, Cancer Type, End Use, and region. Based on Cancer Diagnostics & Treatment, the market is segmented into Cancer Diagnostics (Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization), Cancer Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy). Based on Cancer Type, the market is segmented into Lung Cancer, Prostate Cancer, Colon & Rectal Cancer, Gastric Cancer, Esophageal Cancer, Liver Cancer, and Breast Cancer. Based on End Use, the market is segmented into Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia, Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Oncology Market

The global oncology market is poised for significant growth, primarily driven by the alarming rise in cancer prevalence worldwide, currently the second leading cause of death after cardiovascular diseases. Factors such as tobacco use, shifting dietary habits, and an increase in life expectancy contribute to this surge, with the World Health Organization projecting new cancer cases to skyrocket from 18.1 million in 2018 to an anticipated 29.4 million by 2040. This escalating burden necessitates effective oncology medications, thereby bolstering market demand. Furthermore, heightened public awareness of cancer risks and treatment options is expected to further stimulate market expansion in the coming years.

Restraints in the Global Oncology Market

The global oncology market faces several significant restraints that hinder its growth trajectory. Adverse drug effects associated with chemotherapy, such as bone marrow suppression, gastrointestinal disorders, neuropathies, and hair loss, not only compromise patient quality of life but also lead to treatment discontinuation, thereby limiting market expansion. Additionally, stringent regulatory frameworks governing drug approvals and high medication costs pose significant barriers for pharmaceutical companies. Furthermore, the impending patent expirations of key oncology drugs introduce competitive pressures, causing a decline in revenue for innovators and stalling investment in new therapies. Collectively, these factors present formidable challenges to the market's progress in the coming years.

Market Trends of the Global Oncology Market

The Global Oncology market is witnessing a robust trend of expansion, driven by an intensified focus on research and development (R&D) for advanced drug therapies, particularly in immunotherapy. As cancer treatment increasingly prioritizes curing the disease, prolonging survival, and enhancing patients' quality of life, market leaders are channeling significant investments into immunotherapy research. The collaboration between companies like FUJIFILM Corporation and the National Cancer Center Japan highlights a growing emphasis on innovative treatments that leverage immune cells to combat tumors. This strategic shift towards effective immunotherapeutic solutions is not only improving patient outcomes but also propelling substantial growth within the oncology sector.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Regulatory Analysis
• Case Study Analysis
• Technology Analysis
• Pricing Analysis
• Clinical Trials

Oncology Market, By Cancer Diagnostics & Treatment

• Market Overview
• Cancer Diagnostics
  • Biopsy
  • Imaging
  • Immunohistochemistry
  • Tumor Biomarkers Test
  • In Situ Hybridization
  • Liquid Biopsy
• Cancer Treatment
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Others

Oncology Market, By Indication

• Market Overview
• Lungs Cancer
• Colorectal Cancer
• Breast Cancer
• Liver Cancer
• Bladder Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

Oncology Market, By End Use

• Market Overview
• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Academia
• Specialty clinics
• Others

Oncology Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (acquired by Bristol-Myers Squibb)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seagen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments